title: The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer.
abstract: Radiotherapy can convert malignant cells into an in situ anticancer vaccine, but is often inadequate at generating sufficient pro-inflammatory signals to optimally activate innate and adaptive immune responses. Topical imiquimod is a powerful pro-inflammatory agent with clinical activity against superficial skin cancers. These two modalities appear to complement each other, hence achieving local and systemic tumor control.
authors.affiliation: Department of Pathology; New York University School of Medicine; New York, NY USA ; Department of Radiation Oncology; New York University School of Medicine; New York, NY USA ; NYU Cancer Institute; New York, NY USA.
authors.forename: Sandra
authors.initials: S
authors.lastname: Demaria
authors.affiliation: Department of Pathology; New York University School of Medicine; New York, NY USA ; NYU Cancer Institute; New York, NY USA.
authors.forename: Claire
authors.initials: C
authors.lastname: Vanpouille-Box
authors.affiliation: Department of Radiation Oncology; New York University School of Medicine; New York, NY USA ; NYU Cancer Institute; New York, NY USA.
authors.forename: Silvia C
authors.initials: SC
authors.lastname: Formenti
authors.affiliation: NYU Cancer Institute; New York, NY USA ; Departmet of Medicine; New York University School of Medicine; New York, NY USA.
authors.forename: Sylvia
authors.initials: S
authors.lastname: Adams
keywords: T cells; Toll-like receptor 7; abscopal effect; breast cancer; cutaneous metastases; cyclophosphamide; immunological adjuvant; radiotherapy; synergy; tumor rejection